Renal Failure with CC DRG - Reimbursement & Medicare

Summary & Overview

Renal Failure with CC: Inpatient Reimbursement Overview

DRG 683 addresses inpatient renal failure cases with at least one Complication or Comorbidity and defines the clinical scope for payment impact. It matters because the Complication or Comorbidity level influences Medicare Severity Diagnosis-Related Group assignment and resultant inpatient reimbursement.

Renal FailureDRG Renal Failure with CCDRG 683Diagnosis-Related GroupInpatient ReimbursementMedicareNephrologyAcute Kidney InjuryChronic Kidney Disease

DRG 683 Overview

DRG 683 covers inpatient stays for renal failure with at least one Complication or Comorbidity. It encompasses acute and chronic kidney failure presentations when an associated condition increases resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity elevates relative payment compared with renal failure cases without comorbidities, reflecting higher expected hospital resource consumption. Accurate clinical coding of renal failure and related comorbid conditions affects reimbursement and case mix classification.

National Payment Rates

Commercial payer rates for DRG 683 span roughly from $8.5K to $18K across the payers listed, with individual payer medians ranging from $8.5K (BCBS) up to $16K (Aetna). The widest spread between payer medians and maximums appears among Anthem and Aetna payers, with maximums reported up to $34K and $25K respectively. See the table and chart below for payer-specific distributions and percentile detail.

Mean Rates by Payer — National — DRG 683

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 683. These values reflect nationwide Medicare payment and charge averages for the covered cases in 2023.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

DRG 683 in Alaska shows a narrow rate band for Anthem and Blue Cross Blue Shield at $14K each, while Cigna displays a broader distribution with a mean of $21K and a max of $35K, producing the largest intra-state variance. The presence of Cigna’s higher mean stands out versus national medians and contributes the most notable deviation from national averages. Refer to the table and chart below for payer-specific percentiles and the full distribution.

Key Insights for Alaska

Anthem is the highest-paying payer in Alaska (mean $14K), while Blue Cross Blue Shield is the lowest-paying payer (mean $14K); Cigna shows the widest spread with a mean of $21K and a max of $35K.
Alaska rates are generally clustered at $14K for Anthem and BCBS, but Cigna’s mean of $21K meaningfully exceeds the clustered state rates and is higher than typical national medians, representing the most notable deviation from national patterns.

Clinical Trials

Acute renal support and early intervention trials: Studies examining timing, modality, and protocols for acute kidney replacement therapies (including intensive hemodialysis/CRRT initiation thresholds, anticoagulation strategies, and fluid management) in hospitalized patients with acute renal failure complicated by comorbidities. These trials enroll patients with new or worsening renal failure during an inpatient stay—often critically ill or hemodynamically unstable—and test whether earlier or protocolized interventions reduce progression to sustained renal replacement therapy or multiorgan failure. This research is directly relevant to inpatient clinicians and payers because optimal acute management may shorten length of stay, lower ICU resource use, and reduce downstream costs associated with chronic dialysis dependence.
Comparative effectiveness studies of bundled inpatient care pathways and complication prevention: Trials or pragmatic comparative studies that evaluate care bundles (e.g., nephrotoxin stewardship, contrast-sparing imaging protocols, optimized hemodynamic management, and standardized electrolyte/acid–base protocols) versus usual care for patients admitted with renal failure and at-risk comorbid conditions. These studies target heterogeneous hospital populations with renal dysfunction and common CCs (sepsis, heart failure, liver disease) to determine which multidisciplinary pathways reduce in-hospital complications, readmissions for renal or cardiovascular issues, and rates of progression to chronic kidney disease. Findings inform hospitals and payers about which care coordination and quality improvement investments most effectively reduce complications and total cost of care for this high-risk DRG.
Post-discharge outcomes and transitional care interventions: Research focused on post-discharge follow-up models, such as early nephrology clinic visits, pharmacist-led medication reconciliation, home lab monitoring, or telehealth monitoring for patients discharged after an inpatient renal failure episode to prevent readmission and monitor recovery of renal function. These cohort studies or randomized trials enroll survivors of inpatient renal failure—often older adults with multimorbidity and polypharmacy—and measure outcomes like renal recovery, 30- and 90-day readmissions, and progression to chronic dialysis. Payers and healthcare systems use this evidence to design transitional care programs that reduce costly readmissions and long-term dialysis initiation, aligning clinical outcomes with reimbursement and value-based care goals.

Transurethral Procedures without CC/MCC: Inpatient Reimbursement Overview

672-URETHRAL-PROCEDURES-WITHOUT-CC-MCC

Urethral Procedures without CC/MCC: Inpatient Reimbursement Overview

698-OTHER-KIDNEY-AND-URINARY-TRACT-DIAGNOSES-WITH-MCC

Other Kidney and Urinary Tract Diagnoses with MCC: Inpatient Reimbursement Overview

662-MINOR-BLADDER-PROCEDURES-WITH-MCC

Minor Bladder Procedures with MCC: Inpatient Reimbursement Overview

655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

687-KIDNEY-AND-URINARY-TRACT-NEOPLASMS-WITH-CC

Kidney and Urinary Tract Neoplasms with CC: Inpatient Reimbursement Overview

688-KIDNEY-AND-URINARY-TRACT-NEOPLASMS-WITHOUT-CC-MCC

Kidney and Urinary Tract Neoplasms without CC/MCC: Inpatient Reimbursement Overview

684-RENAL-FAILURE-WITHOUT-CC-MCC

Renal Failure without CC/MCC: Inpatient Reimbursement Overview

650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

Showing 1–10 of 41

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$8.3K	$39K	$6.4K	82K